Trade BIIB anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Biogen Inc. (BIIB) is trading at US$217.48, down 1.82% today as of Aug 28, 11:58 EDT. The company has a market capitalisation of US$32.03B. Over the past 52 weeks, BIIB has traded between US$131.52 and US$222.85. On Syfe you can trade BIIB with $0 commission and add it to your watchlist.
| Previous close | US$221.50 |
|---|---|
| Market cap | US$32.03B |
| P/E ratio | 14.36 |
| 52-week range | US$131.52 – US$222.85 |
| Volume | 489.13K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Biogen Inc.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Year: 1991
Biogen Inc. (BIIB) stock is trading at US$217.48, -1.82% from the previous close of US$221.50.
The market cap for Biogen Inc. (BIIB) stock is approximately US$32.03B.
The price-to-earnings ratio for Biogen Inc. (BIIB) is 14.36, based on the latest reported earnings.
The 52-week high for Biogen Inc. (BIIB) stock is US$222.85.
The 52-week low for Biogen Inc. (BIIB) stock is US$131.52.
Biogen Inc. (BIIB) does not currently pay a dividend.
Stay on top of BIIB
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
